Ligand Pharmaceuticals (LGND) Net Income towards Common Stockholders (QoQ) (2010 - 2026)
Ligand Pharmaceuticals (LGND) Net Income towards Common Stockholders (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Ligand Pharmaceuticals | 5.92 Bn | 5.14 Bn | 48.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -129.80% |
| Dec 31, 2025 | -61.81% |
| Sep 30, 2025 | 2,319.50% |
| Jun 30, 2025 | 111.42% |
| Mar 31, 2025 | -36.55% |
| Mar 31, 2023 | 43.58% |
| Dec 31, 2022 | 68.07% |
| Sep 30, 2022 | 31.52% |
| Jun 30, 2022 | -449.43% |
| Mar 31, 2022 | -10.48% |
| Dec 31, 2021 | 66.39% |
| Sep 30, 2021 | -15.71% |
| Jun 30, 2021 | -22.68% |
| Mar 31, 2021 | -126.49% |
| Dec 31, 2020 | 362.51% |
| Sep 30, 2020 | -130.34% |
| Jun 30, 2020 | 191.53% |
| Mar 31, 2020 | -227.64% |
| Dec 31, 2019 | 51.71% |
| Sep 30, 2019 | -5.77% |